0000000000328701

AUTHOR

Nervin Lawendy

showing 1 related works from this author

DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but …

2019

medicine.medical_specialtyTofacitinibOctave (poetry)business.industryOPEN LABEL TREATMENTGastroenterologyGeneral Medicinemedicine.diseaseUlcerative colitisMaintenance therapyInternal medicinemedicineIn patientbusinessJournal of Crohn's and Colitis
researchProduct